O	0	14	Antiangiogenic	Antiangiogenic	JJ	B-NP
O	15	18	and	and	CC	I-NP
B-Cancer	19	28	antitumor	antitumor	JJ	I-NP
O	29	36	effects	effect	NNS	I-NP
O	37	39	of	of	IN	B-PP
O	40	41	a	a	DT	B-NP
O	42	49	protein	protein	NN	I-NP
O	50	56	kinase	kinase	NN	I-NP
O	57	62	Cbeta	Cbeta	NN	I-NP
O	63	72	inhibitor	inhibitor	NN	I-NP
O	73	75	in	in	IN	B-PP
O	76	81	human	human	JJ	B-NP
B-Cancer	82	88	breast	breast	NN	I-NP
I-Cancer	89	95	cancer	cancer	NN	I-NP
O	96	99	and	and	CC	O
B-Cancer	100	107	ovarian	ovarian	JJ	B-NP
I-Cancer	108	114	cancer	cancer	NN	I-NP
I-Cancer	115	125	xenografts	xenograft	NNS	I-NP
O	125	126	.	.	.	O

O	127	129	In	In	IN	B-PP
B-Cell	130	134	cell	cell	NN	B-NP
I-Cell	135	142	culture	culture	NN	I-NP
O	142	143	,	,	,	O
O	144	147	the	the	DT	B-NP
O	148	156	compound	compound	NN	I-NP
O	157	163	317615	317615	CD	I-NP
O	164	168	2HCl	2HCl	NN	I-NP
O	168	169	,	,	,	O
O	170	171	a	a	DT	B-NP
O	172	178	potent	potent	JJ	I-NP
O	179	188	inhibitor	inhibitor	NN	I-NP
O	189	191	of	of	IN	B-PP
O	192	196	VEGF	VEGF	NN	B-NP
O	196	197	-	-	HYPH	B-NP
O	197	207	stimulated	stimulate	VBN	I-NP
B-Cell	208	213	HUVEC	HUVEC	NN	I-NP
O	214	227	proliferation	proliferation	NN	I-NP
O	227	228	,	,	,	O
O	229	232	was	be	VBD	B-VP
O	233	236	not	not	RB	O
O	237	241	very	very	RB	B-ADJP
O	242	251	effective	effective	JJ	I-ADJP
O	252	259	against	against	IN	B-PP
B-Cell	260	262	MX	MX	NN	B-NP
I-Cell	262	263	-	-	HYPH	B-NP
I-Cell	263	264	1	1	CD	I-NP
I-Cell	265	271	breast	breast	NN	I-NP
I-Cell	272	278	cancer	cancer	NN	I-NP
I-Cell	279	284	cells	cell	NNS	I-NP
O	285	286	(	(	(	O
O	286	290	IC50	IC50	NN	B-NP
O	290	291	=	=	SYM	B-VP
O	292	293	8	8	CD	B-NP
O	293	294	.	.	SYM	I-NP
O	294	295	1	1	CD	I-NP
O	296	302	microM	microM	NN	I-NP
O	302	303	)	)	)	O
O	304	306	or	or	CC	O
B-Cell	307	311	SKOV	SKOV	NN	B-NP
I-Cell	311	312	-	-	HYPH	O
I-Cell	312	313	3	3	CD	B-NP
I-Cell	314	321	ovarian	ovarian	JJ	I-NP
I-Cell	322	331	carcinoma	carcinoma	NN	I-NP
I-Cell	332	337	cells	cell	NNS	I-NP
O	338	339	(	(	(	O
O	339	343	IC50	IC50	NN	B-NP
O	344	345	=	=	SYM	B-VP
O	346	347	9	9	CD	B-NP
O	347	348	.	.	SYM	I-NP
O	348	349	5	5	CD	I-NP
O	350	356	microM	microM	NN	I-NP
O	356	357	)	)	)	O
O	357	358	.	.	.	O

O	359	367	Exposure	Exposure	NN	B-NP
O	368	370	to	to	TO	B-PP
O	371	383	combinations	combination	NNS	B-NP
O	384	386	of	of	IN	B-PP
O	387	397	paclitaxel	paclitaxel	NN	B-NP
O	398	400	or	or	CC	I-NP
O	401	412	carboplatin	carboplatin	NN	I-NP
O	413	416	and	and	CC	O
O	417	423	317615	317615	CD	B-NP
O	424	425	x	x	NN	I-NP
O	426	430	2HCl	2HCl	NN	I-NP
O	431	435	with	with	IN	B-PP
B-Cell	436	438	MX	MX	NN	B-NP
I-Cell	438	439	-	-	HYPH	B-NP
I-Cell	439	440	1	1	CD	I-NP
I-Cell	441	446	cells	cell	NNS	I-NP
O	447	449	in	in	IN	B-PP
O	450	457	culture	culture	NN	B-NP
O	458	466	resulted	result	VBD	B-VP
O	467	469	in	in	IN	B-PP
B-Cell	470	474	cell	cell	NN	B-NP
O	475	483	survival	survival	NN	I-NP
O	484	488	that	that	WDT	B-NP
O	489	498	reflected	reflect	VBD	B-VP
O	499	508	primarily	primarily	RB	B-NP
O	509	519	additivity	additivity	NN	I-NP
O	520	522	of	of	IN	B-PP
O	523	526	the	the	DT	B-NP
O	527	530	two	two	CD	I-NP
O	531	537	agents	agent	NNS	I-NP
O	537	538	.	.	.	O

O	539	547	Exposure	Exposure	NN	B-NP
O	548	550	of	of	IN	B-PP
B-Cell	551	555	SKOV	SKOV	NN	B-NP
I-Cell	555	556	-	-	HYPH	B-NP
I-Cell	556	557	3	3	CD	I-NP
I-Cell	558	563	cells	cell	NNS	I-NP
O	564	566	to	to	TO	B-PP
O	567	577	paclitaxel	paclitaxel	NN	B-NP
O	578	580	or	or	CC	I-NP
O	581	592	carboplatin	carboplatin	NN	I-NP
O	593	598	along	along	IN	B-PP
O	599	603	with	with	IN	B-PP
O	604	610	317615	317615	CD	B-NP
O	611	615	2HCl	2HCl	NN	I-NP
O	616	624	resulted	result	VBD	B-VP
O	625	627	in	in	IN	B-PP
B-Cell	628	632	cell	cell	NN	B-NP
O	633	642	survivals	survival	NNS	I-NP
O	643	647	that	that	WDT	B-NP
O	648	657	reflected	reflect	VBD	B-VP
O	658	668	additivity	additivity	NN	B-NP
O	669	671	of	of	IN	B-PP
O	672	678	317615	317615	CD	B-NP
O	679	680	x	x	SYM	I-NP
O	681	685	2HCl	2HCl	NN	I-NP
O	686	690	with	with	IN	B-PP
O	691	701	paclitaxel	paclitaxel	NN	B-NP
O	702	705	and	and	CC	O
O	706	713	greater	great	JJR	B-ADJP
O	713	714	-	-	HYPH	O
O	714	718	than	than	IN	B-PP
O	718	719	-	-	HYPH	B-NP
O	719	727	additive	additive	JJ	I-NP
O	728	740	cytotoxicity	cytotoxicity	NN	I-NP
O	741	745	with	with	IN	B-PP
O	746	757	carboplatin	carboplatin	NN	B-NP
O	757	758	.	.	.	O

O	759	773	Administration	Administration	NN	B-NP
O	774	776	of	of	IN	B-PP
O	777	783	317615	317615	CD	B-NP
O	784	785	x	x	SYM	I-NP
O	786	790	2HCI	2HCI	NN	I-NP
B-Organism_subdivision	791	797	orally	orally	RB	B-ADVP
O	798	803	twice	twice	RB	I-ADVP
O	804	809	daily	daily	RB	B-ADVP
O	810	812	to	to	TO	B-PP
O	813	817	nude	nude	JJ	B-NP
O	818	822	mice	mouse	NNS	I-NP
O	823	830	bearing	bear	VBG	B-VP
B-Cancer	831	843	subcutaneous	subcutaneous	JJ	B-NP
I-Cancer	844	846	MX	MX	NN	I-NP
I-Cancer	846	847	-	-	HYPH	B-NP
I-Cancer	847	848	1	1	CD	I-NP
I-Cancer	849	855	tumors	tumor	NNS	I-NP
O	856	858	or	or	CC	I-NP
B-Cancer	859	863	SKOV	SKOV	NN	I-NP
I-Cancer	863	864	-	-	HYPH	B-NP
I-Cancer	864	865	3	3	CD	I-NP
I-Cancer	866	872	tumors	tumor	NNS	I-NP
O	873	881	resulted	result	VBD	B-VP
O	882	884	in	in	IN	B-PP
O	885	886	a	a	DT	B-NP
O	887	896	decreased	decrease	VBN	I-NP
O	897	903	number	number	NN	I-NP
O	904	906	of	of	IN	B-PP
B-Multi-tissue_structure	907	919	intratumoral	intratumoral	JJ	B-NP
I-Multi-tissue_structure	920	927	vessels	vessel	NNS	I-NP
O	928	930	as	as	IN	B-SBAR
O	931	941	determined	determine	VBN	B-VP
O	942	944	by	by	IN	B-PP
O	945	949	CD31	CD31	NN	B-NP
O	950	953	and	and	CC	I-NP
O	954	959	CD105	CD105	NN	I-NP
O	960	968	staining	staining	NN	I-NP
O	969	973	with	with	IN	B-PP
O	974	983	decreases	decrease	NNS	B-NP
O	984	986	of	of	IN	B-PP
O	987	989	35	35	CD	B-NP
O	989	990	%	%	NN	I-NP
O	991	994	and	and	CC	O
O	995	997	43	43	CD	B-NP
O	997	998	%	%	NN	I-NP
O	999	1001	in	in	IN	B-PP
B-Cancer	1002	1004	MX	MX	NN	B-NP
I-Cancer	1004	1005	-	-	HYPH	B-NP
I-Cancer	1005	1006	1	1	CD	I-NP
I-Cancer	1007	1013	tumors	tumor	NNS	I-NP
O	1014	1017	and	and	CC	O
O	1018	1020	60	60	CD	B-NP
O	1020	1021	%	%	NN	I-NP
O	1022	1025	and	and	CC	O
O	1026	1028	75	75	CD	B-NP
O	1028	1029	%	%	NN	I-NP
O	1030	1032	in	in	IN	B-PP
B-Cancer	1033	1037	SKOV	SKOV	NN	B-NP
I-Cancer	1037	1038	-	-	HYPH	B-NP
I-Cancer	1038	1039	3	3	CD	I-NP
I-Cancer	1040	1046	tumors	tumor	NNS	I-NP
O	1046	1047	,	,	,	O
O	1048	1060	respectively	respectively	RB	B-ADVP
O	1060	1061	.	.	.	O

O	1062	1068	317615	317615	CD	B-NP
O	1069	1070	x	x	NN	I-NP
O	1071	1075	2HCl	2HCl	NN	I-NP
O	1076	1079	was	be	VBD	B-VP
O	1080	1082	an	an	DT	B-NP
O	1083	1089	active	active	JJ	I-NP
B-Cancer	1090	1099	antitumor	antitumor	JJ	I-NP
O	1100	1105	agent	agent	NN	I-NP
O	1106	1113	against	against	IN	B-PP
O	1114	1117	the	the	DT	B-NP
B-Cancer	1118	1120	MX	MX	NN	I-NP
I-Cancer	1120	1121	-	-	HYPH	B-NP
I-Cancer	1121	1122	1	1	CD	I-NP
I-Cancer	1123	1132	xenograft	xenograft	NN	I-NP
O	1133	1136	and	and	CC	O
O	1137	1146	increased	increase	VBD	B-VP
O	1147	1150	the	the	DT	B-NP
B-Cancer	1151	1156	tumor	tumor	NN	I-NP
O	1157	1163	growth	growth	NN	I-NP
O	1164	1169	delay	delay	NN	I-NP
O	1170	1178	produced	produce	VBN	B-VP
O	1179	1181	by	by	IN	B-PP
O	1182	1192	paclitaxel	paclitaxel	NN	B-NP
O	1193	1195	by	by	IN	B-PP
O	1196	1197	1	1	CD	B-NP
O	1197	1198	.	.	.	I-NP
O	1198	1199	7	7	CD	I-NP
O	1199	1200	-	-	HYPH	O
O	1200	1204	fold	fold	RB	B-ADVP
O	1205	1208	and	and	CC	O
O	1209	1212	the	the	DT	B-NP
B-Cancer	1213	1218	tumor	tumor	NN	I-NP
O	1219	1225	growth	growth	NN	I-NP
O	1226	1231	delay	delay	NN	I-NP
O	1232	1240	produced	produce	VBN	B-VP
O	1241	1243	by	by	IN	B-PP
O	1244	1255	carboplatin	carboplatin	NN	B-NP
O	1256	1258	by	by	IN	B-PP
O	1259	1260	3	3	CD	B-NP
O	1260	1261	.	.	SYM	I-NP
O	1261	1262	8	8	CD	I-NP
O	1262	1263	-	-	HYPH	I-NP
O	1263	1267	fold	fold	RB	B-ADVP
O	1267	1268	.	.	.	O

O	1269	1283	Administration	Administration	NN	B-NP
O	1284	1286	of	of	IN	B-PP
O	1287	1293	317615	317615	CD	B-NP
O	1294	1295	x	x	SYM	I-NP
O	1296	1300	2HCl	2HCl	NN	I-NP
O	1301	1305	also	also	RB	B-ADVP
O	1306	1315	increased	increase	VBD	B-VP
O	1316	1319	the	the	DT	B-NP
B-Cancer	1320	1325	tumor	tumor	NN	I-NP
O	1326	1332	growth	growth	NN	I-NP
O	1333	1338	delay	delay	NN	I-NP
O	1339	1347	produced	produce	VBN	B-VP
O	1348	1350	by	by	IN	B-PP
O	1351	1363	fractionated	fractionate	VBN	B-NP
O	1364	1373	radiation	radiation	NN	I-NP
O	1374	1381	therapy	therapy	NN	I-NP
O	1382	1384	in	in	IN	B-PP
O	1385	1388	the	the	DT	B-NP
B-Cancer	1389	1391	MX	MX	NN	I-NP
I-Cancer	1391	1392	-	-	HYPH	B-NP
I-Cancer	1392	1393	1	1	CD	I-NP
I-Cancer	1394	1399	tumor	tumor	NN	I-NP
O	1399	1400	.	.	.	O

O	1401	1410	Treatment	Treatment	NN	B-NP
O	1411	1415	with	with	IN	B-PP
O	1416	1422	317615	317615	CD	B-NP
O	1423	1424	x	x	SYM	I-NP
O	1425	1429	2HCl	2HCl	NN	I-NP
O	1430	1435	alone	alone	RB	B-ADVP
O	1436	1445	increased	increase	VBD	B-VP
O	1446	1449	the	the	DT	B-NP
O	1450	1458	lifespan	lifespan	NN	I-NP
O	1459	1461	of	of	IN	B-PP
O	1462	1469	animals	animal	NNS	B-NP
O	1470	1477	bearing	bear	VBG	B-VP
B-Cancer	1478	1493	intraperitoneal	intraperitoneal	JJ	B-NP
I-Cancer	1494	1498	SKOV	SKOV	NN	I-NP
I-Cancer	1498	1499	-	-	HYPH	B-NP
I-Cancer	1499	1500	3	3	CD	I-NP
I-Cancer	1501	1511	xenografts	xenograft	NNS	I-NP
O	1512	1514	by	by	IN	B-PP
O	1515	1516	1	1	CD	B-NP
O	1516	1517	.	.	.	O
O	1517	1518	9	9	CD	B-NP
O	1519	1523	fold	fold	JJ	I-NP
O	1524	1532	compared	compare	VBN	B-PP
O	1533	1537	with	with	IN	B-PP
O	1538	1547	untreated	untreated	JJ	B-NP
O	1548	1555	control	control	NN	I-NP
O	1556	1563	animals	animal	NNS	I-NP
O	1563	1564	.	.	.	O

O	1565	1568	The	The	DT	B-NP
O	1569	1580	combination	combination	NN	I-NP
O	1581	1583	of	of	IN	B-PP
O	1584	1594	paclitaxel	paclitaxel	NN	B-NP
O	1595	1598	and	and	CC	O
O	1599	1605	317615	317615	CD	B-NP
O	1606	1607	x	x	NN	I-NP
O	1608	1612	2HCl	2HCl	NN	I-NP
O	1613	1621	resulted	result	VBD	B-VP
O	1622	1624	in	in	IN	B-PP
O	1625	1628	100	100	CD	B-NP
O	1628	1629	%	%	NN	I-NP
O	1630	1633	120	120	CD	B-NP
O	1633	1634	-	-	HYPH	I-NP
O	1634	1637	day	day	NN	I-NP
O	1638	1646	survival	survival	NN	I-NP
O	1647	1649	of	of	IN	B-PP
B-Cancer	1650	1654	SKOV	SKOV	NN	B-NP
I-Cancer	1654	1655	-	-	HYPH	B-NP
I-Cancer	1655	1656	3	3	CD	I-NP
O	1657	1664	bearing	bear	VBG	I-NP
O	1665	1672	animals	animal	NNS	I-NP
O	1672	1673	.	.	.	O

O	1674	1688	Administration	Administration	NN	B-NP
O	1689	1691	of	of	IN	B-PP
O	1692	1698	317615	317615	CD	B-NP
O	1699	1700	x	x	SYM	I-NP
O	1701	1705	2HCl	2HCl	NN	I-NP
O	1706	1711	along	along	IN	B-PP
O	1712	1716	with	with	IN	B-PP
O	1717	1728	carboplatin	carboplatin	NN	B-NP
O	1729	1731	to	to	TO	B-PP
O	1732	1739	animals	animal	NNS	B-NP
O	1740	1747	bearing	bear	VBG	B-VP
O	1748	1751	the	the	DT	B-NP
B-Cancer	1752	1756	SKOV	SKOV	NN	I-NP
I-Cancer	1756	1757	-	-	HYPH	B-NP
I-Cancer	1757	1758	3	3	CD	I-NP
I-Cancer	1759	1764	tumor	tumor	NN	I-NP
O	1765	1773	produced	produce	VBD	B-VP
O	1774	1775	a	a	DT	B-NP
O	1776	1777	1	1	CD	I-NP
O	1777	1778	.	.	.	I-NP
O	1778	1779	8	8	CD	I-NP
O	1779	1780	-	-	HYPH	I-NP
O	1780	1784	fold	fold	JJ	I-NP
O	1785	1793	increase	increase	NN	I-NP
O	1794	1796	in	in	IN	B-PP
O	1797	1805	lifespan	lifespan	NN	B-NP
O	1806	1814	compared	compare	VBN	B-PP
O	1815	1819	with	with	IN	B-PP
O	1820	1831	carboplatin	carboplatin	NN	B-NP
O	1832	1837	alone	alone	RB	B-ADVP
O	1837	1838	.	.	.	O

O	1839	1845	317615	317615	CD	B-NP
O	1846	1847	x	x	NN	I-NP
O	1848	1852	2HCl	2HCl	NN	I-NP
O	1853	1855	is	be	VBZ	B-VP
O	1856	1857	a	a	DT	B-NP
O	1858	1867	promising	promising	JJ	I-NP
O	1868	1871	new	new	JJ	I-NP
O	1872	1886	antiangiogenic	antiangiogenic	JJ	I-NP
O	1887	1892	agent	agent	NN	I-NP
O	1893	1897	that	that	WDT	B-NP
O	1898	1900	is	be	VBZ	B-VP
O	1901	1903	in	in	IN	B-PP
O	1904	1909	early	early	JJ	B-NP
O	1910	1915	phase	phase	NN	I-NP
O	1916	1924	clinical	clinical	JJ	I-NP
O	1925	1932	testing	testing	NN	I-NP
O	1932	1933	.	.	.	O

